CL2018000238A1 - Mezcla de péptidos (divisional solicitud 201601405) - Google Patents
Mezcla de péptidos (divisional solicitud 201601405)Info
- Publication number
- CL2018000238A1 CL2018000238A1 CL2018000238A CL2018000238A CL2018000238A1 CL 2018000238 A1 CL2018000238 A1 CL 2018000238A1 CL 2018000238 A CL2018000238 A CL 2018000238A CL 2018000238 A CL2018000238 A CL 2018000238A CL 2018000238 A1 CL2018000238 A1 CL 2018000238A1
- Authority
- CL
- Chile
- Prior art keywords
- ras protein
- divisional application
- amino acids
- region
- peptide mixture
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 102000016914 ras Proteins Human genes 0.000 abstract 4
- 108010014186 ras Proteins Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
<p>SE DESCRIBE UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNA PREPARACIÓN DE CÉLULAS T Y UN EXCIPIENTE Y / O VEHÍCULO FARMACÉUTICO, EN LA QUE LA PREPARACIÓN DE CÉLULAS T COMPRENDE CÉLULAS T ESPECÍFICAS PARA UN PÉPTIDO CUANDO SE PRESENTAN EN UNA MOLÉCULA DE MHC, DONDE EL PÉPTIDO CORRESPONDE A UN FRAGMENTO DE LA PROTEÍNA RAS Y COMPRENDE UNA REGIÓN DE AL MENOS 8 AMINOÁCIDOS QUE INCLUYE LA POSICIÓN DE AMINOÁCIDOS 12, 13 O 61 DE LA PROTEÍNA RAS, DICHA REGIÓN TIENE AL MENOS 6 RESIDUOS DE AMINOÁCIDOS, DISTINTOS DE DICHA POSICIÓN 12, 13 O 61, QUE SON IDÉNTICOS A LA REGIÓN CORRESPONDIENTE DE LA PROTEÍNA RAS, Y EL PÉPTIDO TIENE UNA SUSTITUCIÓN DE AMINOÁCIDO EN EL AMINOÁCIDO CORRESPONDIENTE A LA POSICIÓN 12, 13 O 61 DE LA PROTEÍNA RAS.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13196333 | 2013-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018000238A1 true CL2018000238A1 (es) | 2018-06-22 |
Family
ID=49765823
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001405A CL2016001405A1 (es) | 2013-12-09 | 2016-06-08 | A peptide mixture |
CL2018000238A CL2018000238A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
CL2018000226A CL2018000226A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
CL2018000232A CL2018000232A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001405A CL2016001405A1 (es) | 2013-12-09 | 2016-06-08 | A peptide mixture |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018000226A CL2018000226A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
CL2018000232A CL2018000232A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
Country Status (24)
Country | Link |
---|---|
US (4) | US9775892B2 (es) |
EP (5) | EP3369432A1 (es) |
JP (2) | JP6781403B2 (es) |
KR (1) | KR20160097290A (es) |
CN (1) | CN105980403A (es) |
AU (2) | AU2014363643B2 (es) |
BR (1) | BR112016013138A2 (es) |
CA (1) | CA2933126A1 (es) |
CL (4) | CL2016001405A1 (es) |
CY (1) | CY1120578T1 (es) |
DK (1) | DK3079715T3 (es) |
ES (1) | ES2682038T3 (es) |
HR (1) | HRP20181213T1 (es) |
HU (1) | HUE039840T2 (es) |
IL (1) | IL246007B2 (es) |
LT (1) | LT3079715T (es) |
MX (1) | MX2016007429A (es) |
PL (1) | PL3079715T3 (es) |
PT (1) | PT3079715T (es) |
RS (1) | RS57623B1 (es) |
RU (1) | RU2016127327A (es) |
SG (2) | SG10201811172PA (es) |
SI (1) | SI3079715T1 (es) |
WO (1) | WO2015086590A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
JP2017514847A (ja) | 2014-05-06 | 2017-06-08 | タルゴバックス エーエスエー | 突然変異rasペプチド及び化学療法剤を含むペプチドワクチン |
CA3051252A1 (en) * | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
WO2018232467A1 (en) | 2017-06-22 | 2018-12-27 | The Westmead Institute for Medical Research | ADOPTIVE T-LYMPHOCYTE THERAPY 2 |
KR20210032393A (ko) * | 2018-06-19 | 2021-03-24 | 바이오엔테크 유에스 인크. | 신생항원 및 이의 용도 |
WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
WO2020041501A1 (en) * | 2018-08-22 | 2020-02-27 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting kras or her2 antigens |
EP3927727A1 (en) | 2019-02-20 | 2021-12-29 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
WO2021009633A1 (en) * | 2019-07-12 | 2021-01-21 | Massey University | Synthetic chromatin vaccine |
CN114651001A (zh) * | 2019-11-07 | 2022-06-21 | 武汉华大吉诺因生物科技有限公司 | 肿瘤免疫治疗多肽及其应用 |
CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
KR102515083B1 (ko) | 2020-12-24 | 2023-03-29 | 부산대학교 산학협력단 | 폴더블 페로브스카이트 태양전지 및 이의 제조 방법 |
CN116867799A (zh) * | 2021-02-10 | 2023-10-10 | 上海吉倍生物技术有限公司 | Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体 |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
WO2023220434A2 (en) * | 2022-05-12 | 2023-11-16 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
WO2024112821A1 (en) * | 2022-11-22 | 2024-05-30 | Elixirgen Therapeutics, Inc. | Antigens for cancer immunotherapy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
NO309798B1 (no) | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
EP1581174B1 (en) | 2002-12-16 | 2018-04-25 | GlobeImmune, Inc. | Yeast-based vaccines as immunotherapy |
ES2330013T3 (es) | 2005-09-05 | 2009-12-03 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas. |
BRPI0709340A2 (pt) * | 2006-03-27 | 2013-04-16 | Globeimmune Inc | mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma |
US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
JP2017514847A (ja) | 2014-05-06 | 2017-06-08 | タルゴバックス エーエスエー | 突然変異rasペプチド及び化学療法剤を含むペプチドワクチン |
-
2014
- 2014-12-09 EP EP18166278.4A patent/EP3369432A1/en active Pending
- 2014-12-09 ES ES14828148.8T patent/ES2682038T3/es active Active
- 2014-12-09 LT LTEP14828148.8T patent/LT3079715T/lt unknown
- 2014-12-09 RU RU2016127327A patent/RU2016127327A/ru not_active Application Discontinuation
- 2014-12-09 CN CN201480074531.3A patent/CN105980403A/zh active Pending
- 2014-12-09 EP EP18166281.8A patent/EP3363458A3/en not_active Withdrawn
- 2014-12-09 EP EP18166279.2A patent/EP3363457A1/en active Pending
- 2014-12-09 DK DK14828148.8T patent/DK3079715T3/en active
- 2014-12-09 KR KR1020167018341A patent/KR20160097290A/ko not_active Application Discontinuation
- 2014-12-09 JP JP2016557194A patent/JP6781403B2/ja active Active
- 2014-12-09 MX MX2016007429A patent/MX2016007429A/es unknown
- 2014-12-09 HU HUE14828148A patent/HUE039840T2/hu unknown
- 2014-12-09 AU AU2014363643A patent/AU2014363643B2/en not_active Ceased
- 2014-12-09 SG SG10201811172PA patent/SG10201811172PA/en unknown
- 2014-12-09 WO PCT/EP2014/077033 patent/WO2015086590A2/en active Application Filing
- 2014-12-09 EP EP14828148.8A patent/EP3079715B1/en active Active
- 2014-12-09 SG SG11201604644QA patent/SG11201604644QA/en unknown
- 2014-12-09 EP EP18164079.8A patent/EP3357505A1/en active Pending
- 2014-12-09 US US15/102,681 patent/US9775892B2/en active Active
- 2014-12-09 PT PT148281488T patent/PT3079715T/pt unknown
- 2014-12-09 SI SI201430776T patent/SI3079715T1/en unknown
- 2014-12-09 RS RS20180907A patent/RS57623B1/sr unknown
- 2014-12-09 CA CA2933126A patent/CA2933126A1/en not_active Abandoned
- 2014-12-09 BR BR112016013138-0A patent/BR112016013138A2/pt not_active Application Discontinuation
- 2014-12-09 PL PL14828148T patent/PL3079715T3/pl unknown
-
2016
- 2016-06-02 IL IL246007A patent/IL246007B2/en unknown
- 2016-06-08 CL CL2016001405A patent/CL2016001405A1/es unknown
-
2017
- 2017-03-17 US US15/461,837 patent/US10335473B2/en active Active
- 2017-08-02 US US15/667,288 patent/US10456457B2/en active Active
- 2017-09-27 US US15/716,861 patent/US10596239B2/en active Active
-
2018
- 2018-01-26 CL CL2018000238A patent/CL2018000238A1/es unknown
- 2018-01-26 CL CL2018000226A patent/CL2018000226A1/es unknown
- 2018-01-26 CL CL2018000232A patent/CL2018000232A1/es unknown
- 2018-07-30 HR HRP20181213TT patent/HRP20181213T1/hr unknown
- 2018-08-10 CY CY20181100846T patent/CY1120578T1/el unknown
-
2019
- 2019-03-20 AU AU2019201937A patent/AU2019201937B2/en not_active Ceased
- 2019-10-04 JP JP2019183442A patent/JP2020023525A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000238A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
CU20190058A7 (es) | Composiciones de aminoácidos relacionadas con mejoras de la función hepática | |
CL2021000516A1 (es) | Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
BR112018004965A2 (pt) | domínios de superfamìlia de imunoglobulina variante ajustàvel | |
BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
BR112015022978A2 (pt) | agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral | |
PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
AR086074A1 (es) | Composiciones y metodo para tratar enfermedades autoinmunes | |
BR112016011224A2 (pt) | Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc | |
PE20142407A1 (es) | Formulacion de anticuerpos | |
AR083295A1 (es) | Metodo para activar celulas t auxiliares | |
EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
AR080914A1 (es) | Proteinas de union al beta-amiloide | |
CL2017003228A1 (es) | Fragmentos mutantes de proteína ras | |
CL2008003784A1 (es) | Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo | |
PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
BR112015021533A2 (pt) | composição curável, método para vedar uma abertura e abertura vedada | |
ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
EA201991409A2 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
EA201691589A1 (ru) | Стабилизированные основанные на фибронектине каркасные молекулы |